







‘Effects of immunomodulatory 































Background. Pancreatic cancer is a devastating malignancy with a 
mortality rate almost identical with its incidence. Thus, the 
development of new therapeutic strategies for treating this cancer is 
absolutely required. A potential novel strategy is targeted 
immunotherapy. The recent discovery of Toll-like receptors (TLRs) 
provides new targets to specifically activate this immunity. Among 
TLRs, TLR9 is expressed by various normal and tumor cells and its 
activation by DNA containing unmethylated CpG motifs leads to a 
cascade of molecular events that culminate in the induction of 
several inflammatory mediators, such as cytokines and nitric oxide 
(NO). 
Aim. The study was performed to demonstrate the presence of TLR9 
in four human pancreatic carcinoma cell lines (PCCs: PP78, PP109, 
PP161, and PP117) and to investigate whether its activation by 
selected oligodeoxynucleotides containing CpG motifs (CpG ODNs) 
could affect the in vitro characteristics of PCCs. 
Methods. TLR9 expression was assessed by using molecular (RT-
PCR and/or real-time PCR, and DNA sequencing), and 
immunological assays (immunofluorescence and Western Blot 
analysis). Cell viability and cell cycle parameters were checked by 
trypan blue exclusion and FACS analysis, respectively. NO 
production was measured by the Griess reagent and cytokine 
production profiles were evaluated using commercial ELISA kits. 
Results. TLR9 mRNA and protein were both expressed at basal 
levels in all PCCs. CpG ODNs treatment of PP78 and PP109 PCCs 
increased the TLR9 expression, and it reduced significantly the cell 





a G0/G1 arrest and decreased the basal level of interleukin (IL)-8 in 
PP78 cells.  
In addition, a significant enhancement in NO production was 
observed in CpG-ODN treated cancer cells. 
Conclusions. Our results indicate that TLR9 ligands produce an 
evident anti-proliferative effect in PCCs; such an effect might depend 
on the CpG-DNA induced modulation of endogenous mediators such 
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1. Pancreatic carcinoma: therapeutic potential 
of toll-like receptor activation 
 
Pancreatic carcinoma is one of the most devastating and lethal 
diseases, with most patients dying within 6 months after diagnosis. 
The main reason for the poor outlook of these patients is that only a 
small number of these tumors are detected in early stages. Because 
the pancreas is located deeply inside the body, early tumors cannot 
be seen or felt by health care providers during routine physical 
exams. Patients usually have no symptoms until the cancer has 
spread to other organs.  
Many efforts have been made to improve the efficacy of treatment 
but the prognosis of pancreatic carcinoma still remains poor. Surgery 
is an option in only 10–15% of the patients, but even after resection, 
recurrence occurs in the majority of the patients, leading to a median 
survival of about 18 months. Chemotherapy is considered the 






chemotherapy drugs used to treat pancreatic cancer include 
gemcitabine, which seems to be the best available treatment option 
improving the quality of life in many patients (El-Rayes et al., 2003). 
However, the drug is capable to prolong survival of pancreatic cancer 
patients of few months only (Burris et al., 1997; Goldstein et al., 
2004). 
Thus, new antitumor therapies for these patients are needed. One 
potential strategy for pancreatic cancer treatment is targeted 
immunotherapy. With growing understanding of the regulation of 
immune responses, multiple new immunotherapeutic targets have 
evolved, and some have reported in several trials prolonged survival 
for immune responders. However, reports of spontaneously 
regressing pancreatic cancer do not exist; this may be because 
pancreatic cancer, as reported above, is generally diagnosed in a 
late stage, when it has already overcome the host immune response.  
The discovery of a series of innate immunospecific receptors 
activated by pathogen-associated molecular patterns may provide 
new possibilities for a targeted activation of this immunity. Among the 
innate immune-specific receptors, the best characterized are the Toll-
like receptors (TLRs; Underhill and Ozinsky, 2002).  
TLRs are evolutionarily well conserved trans-membrane proteins that 
comprise a family of approximately 13 members, depending on 






microbial products; examples include bacterial peptidoglycans, 
lipopolysaccaride (LPS), and flagellin, which are recognized by TLRs 
2, 4, and 5, respectively, and nucleic acid from bacteria and viruses, 
which are recognized by TLRs 3, 7, 8, and 9 (fig. I.1; Akira and 












The signals induced by TLRs are critical for eliciting immune 
responses at both the innate and adaptive levels. 
Although several TLRs reside on the cell surface, such as TLRs 2, 4, 
and 5, nucleic acid recognition by TLRs occurs intracellularly 
(Matsumoto et al., 2003; Leifer et al., 2004; Schmausser et al., 
2004). 
In particular, TLR9, the focus of the current work, is retained in 
endoplasmic reticulum and it responds to bacterial and viral DNA as 
well as synthetic oligodeoxynucleotides (ODNs) that contain 
unmethylated CpG dinucleotides in specific sequence contexts 
(Hemmi et al., 2000). Through TLR9 signaling pathway, 
immunostimulatory CpG sequences activate a complex cascade that 
leads to stimulation of an immune response and increased 
production of proinflammatory cytokines and chemokines (Klinman, 
et al., 1996; Krieg, 2002). 
In humans, TLR9 has been described to be expressed in B-
lymphocytes and plasmacitoid dendritic cells, but an increasing 
evidence suggests that TLR9 expression is not confined to cells of 
immune system; in fact, some studies, have been detected its 
expression in normal epithelial and cancer cells, including breast, 
brain, lung, and gastric cancer cells (Schaefer et al., 2004; 
Schmausser et al., 2004; Droemann et al., 2005; Schamausser et al., 






transcript expression by pancreatic islet cells (Wen et al., 2004; 
Giarratana et al., 2004). 
Over the past years there has been an enormous increase in the 
understanding of the molecular and cellular effects of CpG-ODNs, 
which have been demonstrated to induce a Th-1 response and to 
activate dendritic cells (Roman et al., 1997; Sparwasser et al., 2000). 
In different experimental tumor models and in some clinical trials, 
treatment with synthetic CpG-ODNs alone or in combination with 
chemotherapy or radiotherapy was shown to exert antitumor activity 
(Weigel et al., 2003; Krieg, 2004; Milas et al., 2004). 
Recently, Tepel and co-workers (2006) demonstrated specific CpG-
ODNs to induce significant growth inhibitory effects on orthotopically 
xenotransplanted pancreatic tumours in highly immunodeficient mice. 
Similar results were observed by using chemotherapy combined with 
CpG-ODNs in the orthotopic mouse model of a human pancreatic 
tumor xenograft (Pratesi et al., 2005): repeated treatments with a 
specific CpG-ODN at the end of the complete chemotherapy regimen 
induced an increasing mice survival. The increased survival obtained 
by the combined use of CpG-ODNs and chemotherapy suggests the 
potential of this therapeutic regimen in the clinical setting. 
Thus, the objective of the present work was to extend and further 






2. TLR9 signalling 
 
TLR9 was first cloned and identified as a receptor for unmethylated 
CpG-DNA as well as for bacterial DNA in 2000 (Hemmi, et al., 2000). 
After its identification, the mechanisms of various immune responses 
and the signal transduction pathway mediated by the engagement of 
CpG DNA with TLR9 were clarified. 
TLR consists of leucine-rich repeats (LRRs), a transmembrane 
domain and a cytoplasmic Toll/interleukin-1 receptor homology (TIR) 
domain. TLR9 is localised at the intracellular membrane 
compartment, such as endoplasmic reticulum (ER) and lysosome 
(Latz et al., 2004). 
TLR9 transmits its signals through a specific interaction with an 
adaptor molecule, MyD88, which contains a cytosolic TIR domain 
and a death domain (DD). 
MyD88 in turn interacts with interleukin-1 receptor-associated kinase-
1 (IRAK-1) and IRAK-4 through its DD. IRAK-4 and its kinase activity 
are essential for TLR9-mediated cytokine production (Kawagoe et al., 
2007). 
IRAK-1 is a well known substrate of IRAK-4, and phosphorilated 
IRAK-1 up-regulates its kinase activity, and subsequently recruits 






Down-stream of TRAF6 transforming growth factor β-activated 
kinase 1 (TAK-1) is activated to phosphorylate IκB kinase (IKK) 
complex, which phosphorylates IκB to induce nuclear translocation of 
NF-κB (Wang et al., 2001). 
Moreover, the activated TAK-1 is prerequisite for the activation of 
mitogen activated protein (MAP) kinases, including extracellular 
receptor kinase (ERK), p38, and Jun N-terminal kinase, responsible 
for the induction of the activator protein-1 (AP-1; fig. I.2). 
Transcription factors NF-κB and AP-1 induce in immune cells the 
transcription of different pro-inflammatory cytokine genes, including 
TNF-α, IL-6 and IL-12. 
TLR9, originally localized in the ER, migrates to the endosome when 
the cells are exposed to CpG-DNA (Latz et al., 2004); after the 
translocation of the ligands, endosomal acidification is reported to be 
critical for the signalling of TLR9: chloroquine and other inhibitors of 
endosomal acidification and/or maturation completely block the 
immune effects of CpG-ODN, demonstrating an essential role for this 















Fig. I.2: TLR9-mediated signaling pathway.  
The cytosolic TIR domain of TLR9 recruits the adaptor molecule MyD88 
and other signaling molecules such as IRAK-4, and TRAF6 that are 
required for the signaling complex. The complex in turn activates different 
signaling cascades that lead to the activation of NF-κB and AP-1. 
These activated transcription factors induce diverse immunity-related genes 

















3. Identification of different classes of CpG-
ODNs 
 
Several syntetic CpG-ODNs agonists for TLR9 are currently in 
development for the cancer treatment. 
The molecular structure of these DNA sequences is an important 
parameter capable to affect their biological function.  
In addition to the requirement of unmethylated CpG dinucleotides, 
the activity of the ODNs is dependent upon the sequences flanking 
both the 5’ and 3’ regions of the CpG dinucleotides (and Agrawal and 
kandimalla, 2001; Yu et al., 2001; Krieg, 2002). The 
immunostimulatory effects of the ODNs are enhanced if there is a 
TpC dinucleotide on the 5’ end and if the ODN is pyrimidine rich on 
the 3’ side (Hartmann and  Krieg, 2000; Hartmann et al., 2000). 
Moreover, the immunostimulatory effects depend on the stability of 
ODNs. The unmodified phosphodiester (PO) CpG-ODNs are 
degraded by nucleases within minutes following in vivo 
administration. Backbone modifications, most notably to 
phosphorpthioate (PS), decrease the ODN degradation: this 
nuclease-resistent backbone improves the half-life of ODNs in the 
body from just a few minutes to about 48 hours (Fig.I.3; Boggs, et al., 
1997); thus, for therapeutic application, CpG-ODNs are typically 






The length of ODN sequences is not directly correlated with their 
activation; six base-length CpG-ODNs show immunostimulatory 
activity. Also the immunostimulatory activity of an ODN is determined 
by the number of CpG motifs it contains (usually two to four are 
optimal) and may also be affected by spacing of the CpG motifs and 
by the presence of poly G sequences (Krieg, 1995; Ballas et al., 





Figure I.3: Backbones of native and modified DNA.  
PS ODN differ from native PO DNA only in the substitution of a sulfur for 








There are at least three classes of CpG-ODNs with distinct structural 
characteristics. These different classes, through the TLR9-activation, 
are able to modulate differently the immune system.  
CpG ODNs of class-A have poly-G motifs with PS linkages on both 
ends, with a PO palindromic CpG in the center. CpG-A ODNs induce 
a strong pDC IFN-α secretion; moreover, they are effective for NK-
sensitive tumors, causing NK activation. CpG-ODNs of class-B have 
the CpG dinucleotide in a fully modified PS backbone. These ODNs 
are strong B-cell stimulators but weaker inducers of IFN- α secretion, 
and they are mostly employed into human clinical development in 
oncology.  
A third class of CpG ODNs combines the effects of A-and B-class 
CpG ODNs. These C-class CpG ODNs are wholly phosphorothioate 
modified, they have no poly-G motifs, but they are characterised by 
palindromic sequences combined with stimulatory CpG motifs (table 
I.1; Boggs et al., 1997; Krieg, 2002; Vollmer et al., 2004). 
Recently, a new generation of CpG-ODNs called “immunomers” has 
been developed: immunomers consist of two CpG molecules linked 
at their 3’ ends; these have the dual benefits of two 5’ ends, which 
are necessary for activity, and lack of 3’ ends, which decreases 











Capital letters in ODN sequences indicate 3′ PS internucleotide linkage; 








NNNN  X  NNNN-O-NNNN  X  NNNN 
 
X = CpG, YpG, CpR, YpR 
  
O = Linker 
 
 





Example ODN  
 
GGgggacgatcgtcgGGGGG 
(also known as ODN 2216) 
Structural features 
 
Poly G region at the 3’ and/or 5’ 
ends; usually with a few PS-
modified internucleotide linkages 



















(also known as ODN 2006, CpG 
7909 and PF-3512676) 
 
Fully PS-modified backbone, no 
major 
secondary structure; most 
important CpG motif for 
activating 
human TLR9 is at the 5’ end. 
 
 
Induces very strong 










(also known as ODN 2395) 
 
Fully PS-modified backbone, 1 
or more 
5’ CpG motifs; self-
complementary 
palindrome in middle or 3’ end 
enables formation of duplex or 
hairpin secondary structure. 
 
 
Induces strong B 
cell proliferation 
and differentiation 
Induces pDC IFN- 











ODN internalisation occurs spontaneously in culture without the need 
for uptake enhancers or transfection. ODN uptake by lymphocytes is 
energy and temperature dependent and greatly increased by cell 
activation; it also seems to be receptor mediated, although the 
specific receptors remain largely unknown (Krieg, 2002). The earliest 
steps in the CpG-induced signal transduction pathways can be 
blocked by inhibitors of phosphatidylinositol 3-kinase, which seems to 





















4. Therapeutic application of CpG-ODNs in 
cancer therapy 
 
CpG-ODNs may represent a potential novel immunotherapeutic 
approach to the treatment of cancer. The rationale for investigating 
TLR9 ligands as possible anticancer agents is based on their ability 
to strongly activate both the innate and adaptive immunity (fig.I.5); 
this activation may directly cause antitumor effects and an enhanced 
tumor antigen presentation in a Th1-like cytokine and chemokine 
milieu.   
The application of TLR9 agonists in human cancer therapy may 
include different areas; they can be also used alone to activate innate 
immunity locally and trigger a tumor specific response; they can be 
also used in combination with tumor antigens, DNA vaccines, 
monoclonal antibodies, or dendritic cells. In addition, ODNs can be 
combined with conventional chemotherapy and radiotherapy to 
increased therapeutic effects, and also to reduce host toxicity and 
improve patient immunity against secondary infection after 




























      
BCC, basal cell carcinoma; CR, complete response; DTIC, dacarbazine; MAGE, 
melanoma antigen–encoding gene; PR, partial response; SD, stable disease; SLN, 
sentinel lymph node (Krieg, 2007). 
Treatment Tumor type Phase of 
clinical trial 
Outcome 
Vaccine    
CPG 7909 + MART1 
peptideA 
Melanome Phase I No objective responses, 66 peptide A but~10× 
increase in antitumor CD8+ T cells  (Speiser, 
et al. , 2005) 
CPG 7909 (dose of 0.5 or 1 
mg) + MAGE-3 recombinant 
protein 
Melanome Phase I 2 PR among the 5 patients enrolled in the 1 
mg CPG 7909 cohort; no responses among 
the 8 in the 0.5 mg cohort  (Ojik  et al. , 2002) 







Two late responses with no other treatment 
(Link et al., 2006) 
2 PR and 3 SD; possible association with NK 
cell cytotoxicity (Pashenkov et al. , 2006) 
 Cutaneous T cell 
lymphoma 
BCC,melanoma 
PhaseI/ II  
 
Phase I 
3 CR and 6 PR (Kim et al., 2004) 
 
Local regression of 4/5 BCC and 1/5 
melanoma (Trefzer et al. , 2002) 
 Renal cell Phase I 2 PR (Thompson et al., 2004) 




Phase I 2 minor responses, median survival 7.2 
months; well tolerated  (Carpentier et al. , 
2006) 
Combination therapies    
1018 ISS + Rituximab NHL Phase I Induction of Th1 cytokines and chemokine 
secretion, good safety profile (Friedberg et 
al., 2005) 
PF-3512676 ± DTIC Melanoma Phase II Four PR in PF-3512676/DTIC-combination 
arm; 2 in DTIC-alone arm; no difference in 
survival (Wagner et al.,  2006) 
Taxane/platin ± 
PF-3512676 
NSCLC (1st line) Phase II Response rate doubled in chemotherapy + 
PF-3512676 combination arm compared with 
chemotherapy alone; 1 year survival improved 
to 50% from 33% in chemotherapy alone 
(Manegold et al., 2005) 






4.1 Monotherapy with CpG-ODNs 
 
The potential efficacy of CpG-ODN monotherapy for cancer 
treatment has been demonstrated in a number of animal models. 
Many of these studies have investigated the ability of TLR9 agonists 
to control the growth of solid tumors; the results obtained from these 
experiments suggest that intra-lesional or peritumoral injection of 
CpG-ODNs is required for an antitumor effect (Heckelsmiller et al., 
2002b; Sharma et al., 2003). 
For example, in a murine cervical carcinoma model, mice with 
established subcutaneous tumor treated with CpG-ODNs injected at 
a distant site showed significant tumor regression with the 
consequent improvement of survival (Baines and Celis, 2003). 
Objective responses have been observed in some patients receiving 
CpG-ODNs for the treatment of melanoma, renal cells cancer, basal 
cells carcinoma, or cutaneous T cell lymphoma (Pashenkov et al., 
2006). In particular, CpG-ODNs demonstrated significant clinical 
activity in a phase I trial of intra- and perilesional injections in patients 
with metastatic melanoma or basal cell carcinoma: treatment was 
associated with increased levels of serum interleukin (IL)-6 and IL-
12p40 in some subjects, and cellular infiltrates of CD8+ were 
observed in most lesions after treatment (Trefzer et al., 2002). 
TLR9 agonists have a variety of effects on B cells that may be 






CpG-ODNs are strong mitogens for normal B cells, they preferentially 
induce apoptosis in tumor B cells stimulated through TLR9; however, 
the mechanism responsible of this effect remains unclear. 
The activation of TLR9 on primary malignant B cells up-regulates 
expression of major histocompatibility complex molecules and other 
surface receptor; this increases their capacity to stimulate T cells 
which exert an enhanced T-cell-mediated response to tumor 
expressed on the malignant B cells (Decker et al., 2000; Jahrsdorfer 
et al., 2001; Wooldridge and Weiner, 2003). 
Several clinical studies of single-agent TLR9 agonists have been 
completed in patients with hematologic malignancies; monotherapy 
with TLR9 agonist CpG ODN-2006 (also known as CpG 7909 or PF-
3512676) or another B-class CpG-ODN, 1018 ISS, activates NK cells 
and induces a Th1 cytokine response in patients with B cell 
lymphomas (Link et al., 2006). 
PF-3512676 has also been studied in a phase I trial in patients with 
refractory non-Hodgkin’s lymphoma; in patients receiving PF-
3512676 intravenously up to three times a week, number and 
activation of NK cells increased in most subjects (Link et al., 2006).  
Overall, these results derived from clinical trials of CpG-ODNs as a 
single agent are encouraging for a good safety profile; however, the 
frequency of objective responses in some tumors has been relatively 






combination of therapies with the focus to improve the clinical 
efficacy of administering TLR9 ligands. 
 
4.2 Use of CpG-ODNs as adjuvant in cancer vaccines 
 
The use of antigen pulsed dendritic cells (DC) as tumor vaccines 
represents a new therapeutic approach for cancer. However, one 
potential limitation of this approach is that failure to correctly induce 
the antigen pulsed DC can lead to T cell tolerance or T cell anergy 
rather than the activation of T cell immunity (Kuwana et al., 2001; 
Martin et al., 2002). 
Different studies have demonstrated the use of CpG-ODNs to 
efficiently activate antigen pulsed DC resulting in a productive 
antigen presentation with the consequent induction of strong anti-
tumor immune responses (Heckelsmiller et al., 2002a; Wang et al., 
2002). 
In vivo manipulation of DC using Flt3 ligand (a growth factor for 
dendritic cells) and CpG-ODNs has been shown to allow effective 
presentation of tumor antigen by DC resulting in strong anti-tumor 
responses capable of rejecting established murine B16 melanoma 






Combined DC and TLR9 ligand therapy was also effective to cure 
large chemotherapy resistant murine renal and colon carcinoma 
(Heckelsmiller et al., 2002a). 
In addition, CpG-ODNs have been used as adjuvant with whole cell 
vaccines, tumor antigens, antigenic peptides or cell lysates (Krieg, 
2004). 
The enhancement in antibody responses observed by using TLR9 
ligands was similar one producted by complete Freund’s adjuvant 
(CFA) but without the toxicity associated with CFA (Weiner et al., 
1997); CpG-ODNs were able to induce stronger immune responses 
than those observed by using CFA in combination with the anti-
idiotypic antibody 3H1 which functionally mimics carcinoembryonic 
antigen, a tumor-associated antigen expressed on human colorectal 
carcinoma and other adenocarcinomas (Baral, et al., 2003). 
Moreover, TLR9 agonists have also been shown to increase the 
effectiveness of cancer vaccines by using autologous tumor cells 
transduced with genes expressing cytokines including IL-12, 
granulocyte macrophage colony-stimulating factor (GM-CSF) 
(Sandler et al., 2003; Switaj et al., 2004), and immunomodulators 
such as CD154 (Rieger and Kipps, 2003). 
More recently, PF-3512676 combined with melanoma antigen A 
(Melan-A) analog peptide was used to vaccinate melanoma patients 






vaccine showed a rapid and strong antigen-specific T cell response 
with a frequency of Melan-A specific circulating CD8+T cells 
approximately ten fold higher  than that observed in melanoma 
patients receiving the same tumor vaccine without  PF-3512676.  
These data demonstrate the capacity to CpG-ODNs to promote 
efficacy antigen-specific antitumor CD8+ T cell responses in human 
with advanced cancer. 
 
4.3 Combination therapy with TLR9 agonists 
 
A further method by which CpG-ODN can be used for tumor 
immunotherapy is its combination with monoclonal antibodies (mAb). 
Antitumor antibodies are able to bind to the tumor surface and are 
thought to mediate at least some of their activity through the 
mechanism of antibody-dependent cellular toxicity (ADCC). The 
innate activation by CpG-ODN treatment should improve the 
antitumor effect of antibody immunotherapy by enhancing ADCC 
(Carpentier et al., 2003; Wooldridge and Weiner, 2003). Moreover, 
the addition of CpG-ODNs leads to the activation of NK cells and 
monocytes/macrophages and this capacity plays a substantial role in 






The combination of CpG-ODN with antibody immunotherapy 
improved in a murine lymphoma model the long-term survival from 
approximately 10% to 80% (Wooldridge et al., 1997). 
Recently, a phase I clinical trial has investigated the combination of a 
CpG-ODN with rituximab, a mAb against CD20, in patients with 
relapsed/refractory non-Hodgkin’s lymphoma. In this study, 50 
patients received PF-3512676 weekly for 4 weeks in combination 
with rituximab: twelve patients (24%) showed an objective response 
(Leonard et al., 2007).  
Combination therapy with TLR9 agonists is being further evaluated 
for antitumor activity in a phase I/II trial in combination with radiation 
therapy and in a phase II trial in combination with rituximab. 
Several preclinical models have also suggested that TLR9 ligands 
can synergize with cytotoxic chemotherapy. CpG-ODNs have been 
reported to enhance the antitumor effects of a number of different 
chemotherapeutic agents such as the topoisomerase I inhibitor, 
topotecan (Balsari et al., 2004), the alkilating agent 
cyclophosphamide (Weigel et al., 2003) and the anti-metabolite 5-
fluorouracil (Wang et al., 2005b). 
Chemotherapeutic agents are known to cause tumor cell death. 
Thus, it’s possible that the cancer bulking, as a result of 
chemotherapy, can provoke the release of tumor-associated antigen 






The employ of chemotherapeutic agents in combination with CpG-
ODNs, which are potent adjuvants, could lead to the activation of 
strong tumor-specific immune responses that would be capable of 
mediating tumor rejection. 
TLR9 ligands were tested in combination with either 
cyclophosphamide or topotecan in an orthotopic rhabdomyosarcoma 
model; the results showed that the combination therapy using CpG-
ODNs and either of chemotherapy drugs enabled the long-term 
survival of 15-40% of the mice with a large tumor. This survival 
benefit required principally the presence  of T cells, but not NK cells, 
suggesting that the CpG-ODNs may have induced the development 
of anti-tumor T cell response; probably this response may have been 
sufficient to eliminate the residual tumor after chemotherapy (Weigel 
et al., 2003) . 
Balsari et al., (2004), showed in a human prostate carcinoma 
xenograft model therapeutic benefits by using CpG-ODNs in 
combination with topotecan chemotherapy. All combined treatment 
resulted in a delay of tumor growth, compared to the effects in 
topotecan-treated mice. 
In some recent studies PF-3512676 in combination with standard 
chemotherapy was evaluated in a randomized phase II clinical trial in 
patients with advanced non-small cell lung cancer. Preliminary data 






achieved objective tumor responses more often than subjects given 
chemotherapy alone. Moreover, PF-3512676 was well tolerated and 
it did not lead to any clinical significant increase in chemotherapy 
related-toxicity (Murad et al., 2007; Manegold et al., 2008). 
More recently, was also evaluated the efficacy of immunomers in 
combination with the chemotherapeutic agents docetaxel and 
doxorubicin in melanoma and breast carcinoma models (Wang et al., 
2004): this approach resulted in synergistic antitumor effects in both 
tumors. This second-generation of immunomer compounds 
possesses antitumor activity in a broad spectrum of tumor models, 







4.4 Safety of TLR9 ligands 
 
It is generally accepted that TLR9 agonists have a favorable safety 
profile. 
Recently, many progresses have been made in understanding the 
immunological and pharmacological effects of the first-generation 
CpG-ODN molecules. However the data available on optimized CpG-
ODNs  in human clinical trials aren’t yet sufficient. 
Preliminary results from early-stage clinical trials of CpG-ODNs used 
as monotherapy or adjuvant in cancer treatment, suggest that this 
therapeutic approach is generally well tolerated; moreover, the 
toxicity observed in humans appears limitated. 
The most common adverse events observed following administration 
of TLR9 agonists are local injection-site reactions (for example, 
erythema, edema, inflammation and pain) or systemic flu-like 
symptoms (for example, headache, rigors, pyrexia, nausea and 
vomiting). These symptoms typically develop 24 hours after dosing 
and are transient, generally lasting for less than 2 days (Krieg, 2006). 
Because of the strong immune stimulatory effects obtained after 
CpG-ODN-treatment, one may expect that CpG would cause 
autoimmune diseases.  However, in spite of early suggestions that 
TLR9 ligands may be a trigger for systemic lupus erythematosus, 






neither causes nor aggravates autoimmune disease, but on the 




























5. Direct effects of CpG-ODNs in TLR9 
expressing cancer cells  
 
CpG ODNs may have an additional mechanism of antitumor activity 
in the treatment of tumors that express TLR9. 
In fact, although it is generally assumed  that TLR9 is principally 
expressed in certain immune cells, tumors may also express this 
receptor. 
Cancer cells expressing TLR9 can be stimulated by CpG-ODNs, 
resulting in similar up-regulation of cytokines and activation of other 
molecules such as AP1 and NF-kB, as seen on normal antigen-
presenting cells (Decker et al., 2000). However, the mechanisms that 
regulate this activation may be different between cancer cells 
expressing TLR9 and immune cells. 
CpG-ODNs have been reported to up-regulate the expression of 
MHC class I and II molecules as well as a variety of primary 
malignant B cells, including various lymphomas and B-cell chronic 
lymphocytic leukaemia (B-CLL) cells (Decker et al., 2000; 
Jahrsdorfer et al., 2001). 
In a recent study, Jahrsdorfer and co-workers (2005) demonstrated 
that in contrast to the classic understanding of TLR9 ligands as 
inhibitors of apoptosis in healthy B cells (Krieg et al., 1995; 






ODNs induce apoptosis in B-CLL cells; this effect was observed not 
only with CpG-ODNs but also with stimulatory ODNs lacking the 
classical CpG motif. The authors also explored the potential 
mechanism responsible for this effect: they found that apoptosis in B-
CLL cells was dependent on the activation of caspases and was 
accompanied by up-regulation of different members of tumor 
necrosis factor (TNF) receptor family. 
A pilot screening study for both protein and mRNA of TLR9 revealed 
that this receptor is also expressed in lung cancer A549 and in 
prostate cancer PC3 cells. Wang and co-workers examined whether 
TLR9 ligands could have direct effects on A549 cancer cells; 
treatment with TLR9 agonists resulted in increased apoptosis, 
decreased proliferation, and decreased survival of cancer cells 
(Wang et al., 2006). Similar results were observed in PC3 cancer 
cells treated with a second generation immunomer oligonucleotide 
(IMO): this TLR9 agonist induced apoptosis and decreased 
proliferation and survival of PC-3 cells (Rayburn et al., 2006). 
Rayburn and co-workers demonstrated TLR9 expression also in 
human colon cancer cells, and that in vitro cell treatment with a TLR9 
agonist results in decreased proliferation and increased apoptosis in 
a dose-dependent manner. The authors also investigated whether 
the tumor suppressor p53, which is involved in many anti-cancer 






necessary for the antitumor effects observed following treatment with 
TLR9 agonists: the results revealed that p53 does not play a major 
role in the apoptosis induced by CpG-ODNs (Rayburn et al., 2007). 
In summary, in vitro CpG-ODN treatment of cancer cells expressing 
TLR9 results in antitumor effects. However, CpG-ODN effects may 
be different in the different types of cancer. With regards to this 
aspect, recent results from a study on TLR9 agonists and breast 
cancer cells, revealed that TLR9 ligands induce cellular invasion by 
increasing matrix metalloproteinase activity and suggested that 
infections may promote cancer progression through a novel TLR9-
mediated mechanism (Merrell et al., 2006). 
Very little is currently known about TLR9 expression in pancreatic 
carcinoma cells; TLR9 is highly expressed and functional in normal 
pancreatic tissue but its presence and its biological significant in 
pancreatic carcinoma cells are poorly investigated. 
Currently, there is only one study on human pancreatic 
adenocarcinoma cell line PancTuI treated with TLR9 ligands; the 
results derived from this study revealed no significant effect of CpG-
ODNs on cancer cell viability. The only detectable effect under ODN-
treatment was a reduction of thymidine incorporation of about 40%, 
but this reduction was unaffected by concentration or oligonucleotide 
characteristics. However, unlike the in vitro results, the authors 






effects on orthotopically xenotransplanted pancreatic tumors in highly 
immunodeficient mice (Tepel et al., 2006). 
Taken together, these results indicate that the biological significant of 
TLR9 expression in malignant cells requires further investigations. 
Understanding TLR9 function in some tumor cells may provide an 
addition explanation for the antitumor activity of CpG-ODNs observed 
in immune deficient mice, and for differences observed in the 






6. Experimental model for investigation of TLR9 
in pancreatic cancer 
 
Because there is little information available on the biological 
significant of TLR9 in pancreatic cancer, in the present study, we 
decided to focus on TLR9 expression and function in PCCs; 
furthermore, pancreatic cancer for its aggressiveness and low 
survival rate, represents an interesting model to verify if TLR9 ligands 
can really affect the in vitro characteristics of cancer cells.  
For this study we have used 4 human pancreatic carcinoma cell lines 
(PCCs: PP78, PP109, PP117, and PP161) provided by Departments 
of Oncology (University of Pisa) and previously established from 
tumor specimens surgically removed from patients with primary 
Pancreatic Ductal Adenocarcinoma (PDA). 
PCCs reflect primary tumor characteristics at both molecular and 
phenotipic levels. Thus,  they represent a useful research tool to 
investigate the role of TLR9 in pancreatic tumor. 
In particular  PP117, PP109 and PP161, are derived from ordinary 
PDA. In contrast, PP78 cell line has been established from an 
adenosquamous carcinoma. This tumor is a rare variant of PDA 
characterized by a worse clinical outcome than classic PDA. The 







A very recent work has provided a complete characterization of 
PCCs with regard to their genetic, cytostructural and functional 
profiles (Chifenti et al., 2008): some results derived from this study 
revealed the presence of K-Ras, TP53, and CDKN2A gene 
alterations in all 4 of them; these findings agree with the high 
frequency of these mutations in PDA. Moreover, each cell line was 
characterized by a complex and unique karyotype with numerous 
structural and numeric chromosomal abnormalities.  
Cytokeratin 19 positivity, which represents a specific marker for the 
pancreatic duct terminal differentiation, was present in all cell lines 
but undetectable in  PP78 cells suggesting a lower level of 
differentiation in this cell line compared to the remaining cells. Unlike 
cytokeratins, Vimentin, intermediated filament of mesenchimal cells, 
generally absent from differentiated epithelial cells was expressed 
only in PP117 and PP78 cells. These data indicate a different degree 
















 to investigate the experimental impact of specific 
CpG-ODNs or viral DNA on TLR9 transduction 
pathway in human PCCs.  
 
 
Secondary AIM:  






















MATERIALS AND METHODS 
 
 
1. Cell lines 
 
Human PCCs (PP78, PP109, PP117, and PP161), previously 
established from tumor specimens surgically removed from patients 
with primary PDA (Funel et al., 2007), were cultured as monolayer in 
25-cm2 or 75-cm2 flask, routinely passaged by trypsinization and 
maintained at 37° C in a CO2 incubator in complete culture medium 
(RPMI 1640 supplemented with 10% fetal bovine serum, 1% L-
Glutamine and 1% ampicillin-streptomycin).  
PCCs were provided for this study by Departments of Oncology, 
Division of Surgical, Molecular and Ultrastructural Pathology 












2. TLR9 agonists 
 
2.1 Synthetic ODNs 
 
The following synthetic ODNs used for our experiments were 
purchased from InVivoGen (San Diego, CA): ODNs 2006, AP1, and 
1826 containing one or more CpG motifs and ODN 1826-control, 
without CpG motifs, used as negative control. The ODNs were 
dissolved in ultrapure pyrogen-free diluent water and stored in 
aliquots at -20°C until use. All ODNs were synthesized with PS 
backbone which confers both nuclease resistance and improved 
cellular uptake to the ODN.  
The ODN sequences are indicated in Table II.1. 
 
Table II.1: ODN sequences. 
ODNs Sequence 
2006 5'-TCGTCGTTTTGTCGTTTTGTCGTT- 3’ 
AP1 5'- GCTTGATGACTCAGCCGGAA - 3’ 
1826 5'- TCCATGACGTTCCTGACGTT- 3’ 
1826-control 5'- TCCATGAGCTTCCTGAGCTT - 3’ 
 





2.2 Viral DNA 
 
A plasma sample found to be positive for Torque Teno Virus (TTV) 
was used to generate the TTV genome to be used in this study.  
Briefly, an inverse PCR was carried out to obtain a complete TTV 
genome. PCR product was cloned into pDrive Cloning Vector 
(Qiagen, Hilden, Germany) and grown in E. coli cells. After 
recombinant clones extraction, PCR insert was excised by restriction 
enzyme digestions and purified by electrophoresis on 1.5% agarose 
gel. Gel-extracted TTV DNA was purified, concentrated in endotoxin-
free water, and quantified by spectrophotometer (Maggi et al., 
manuscript in preparation). 
Endotoxin contamination of TTV DNA was excluded by Limulus 
amebocyte assay (LAL Pyrotell; International PBI, Milan, Italy).  
TTV DNA was tested with pre-incubation in serum-free medium with 
lipofectin (Lipofectin® Transfection Reagent Life Technologies, 
Carlsband, CA) for 15 minutes at room temperature. The cationic 












3. RT-PCR analysis 
 
Total mRNA was extracted from PCCs by using the RNeasy Mini kit 
(Qiagen) and transformed in cDNA by RevertAid First Strand cDNA 
Synthesis Kit (Fermentas). TLR9 amplification was carried out using 
both a standard set of primers (Pedersen et al., 2005) and a custom 
made set designed in our laboratories (Table II.2); PCR product was 
visualized by electrophoresis on agarose gel and ethidium bromide 
staining. Glyceraldehyde-3-phosphate dehydrogenase (GAPDH) was 
co-amplified with TLR9 to verify the quality and the expression level 
of the mRNA. The specificity of the TLR9 PCR products was 






Forward primer  Reverse primer  PCR product 
size 
H-TLR9  TTCCTCTATTCTCTGAGCCG1  GTAGGAAGGCAGGCAAGGTA1  223bp 
H-TLR9 TGGGATGTAGGCTGTCTGAG2  TGGGCGGGTGGGCAAAGTC2  547bp 
H-GAPDH TGAAGGTCGGAGTCAACGGATTTGGT  CATGTGGGCCATGAGGTCCACCAC  960bp 
 
Table II.2: Oligonucleotide primers used for RT-PCR 
1  Primers from Pedersen et al., 2005.  
 
2  Primers from our laboratories. 
H: human 





4. Quantitative RT-PCR for TLR9 expression  
 
4.1 Semiquantitative RT-PCR 
 
PP109 cells were seeded in 25 cm2 culture flasks (1.5 x 106 
cells/flask), cultured for 24 hours and then stimulated with 3µM ODNs 
for 4 hours. Total RNA was extracted from untreated and ODN-
treated cells. Two µg of total RNA was reverse transcribed into cDNA 
and used as template for PCR. Semiquantitative PCR was then 
performed by using undiluted or 15-fold diluted cDNA samples to 
determine the differential level of TLR9 mRNA expression. 
 
4.2 Real-time RT-PCR  
 
PP78 and PP109 cells were seeded in 25 cm2 culture flasks (1.5 x 
106 cells/flask), cultured for 24 hours and then stimulated with 3µM 
ODNs for 4 and 24 and 72 hours. Total mRNA was extracted from 
untreated and ODN-treated cells, transformed in cDNA and then 
used as template for TLR9 Real Time PCR.  
Real time quantitative PCR analysis was performed on ABI PRISM 
7700 by using commercial available kits with primers and probes 
specific for TLR9 and GAPDH (TaqMan® Gene Expression Assays, 
Applied). The relative expression ratio of the target TLR9 gene was 





computed by the Relative Expression Software Tool (REST; Pfaffl et 
al., 2002), that standardizes the expression of a target gene by a 
non-regulated reference gene. 
 
 
5. TLR9 protein expression  
 
5.1  Immunofluorence analysis 
 
For immunofluorescence labelling, PCCs were grown at low density 
on 8-wells chamber-slides for 24 hours. After washing with PBS the 
cells were fixed with 4% paraformaldehyde for 10 minutes at room 
temperature and then permeabilized with 0,2%-0.3% of Triton X-100 
in PBS. The non-specific binding sites were blocked by incubation 
with 1% bovine serum albumin (BSA) in PBS for 45 minutes at room 
temperature. The cells were then incubated over night at 4°C with the 
primary anti-TLR9 mouse monoclonal antibody (Santa Cruz 
Biotecnology) in 0,1% BSA in PBS. After incubation slides were 
washed with PBS and further incubated with the Alexa fluor-488 
conjugated goat anti-mouse secondary antibody (Molecular Probes, 
Invitrogen) for 2 hours at room temperature. After extensive washes 
the slides were mounted in ProlongGold antifade (Molecular Probes, 





Invitrogen) and observed using a confocal scanning radiance plus 
microscope (Bio-Rad).   
 
5.2 Western Blot analysis  
 
PP78 and PP109 cells at confluence were washed twice with PBS 
and harvested by trypsinization followed by centrifugation. Cells were 
lysed in extraction buffer consisting of  8 mol/L Urea, 4% (w/v) 
CHAPS, 65 mmol/L DTT and the protein concentration was 
determined using a Bradford assay (Bio-Rad). Fifty µg of the total 
protein extraction of each sample were separated by 10% SDS-
PAGE and transferred to nitrocellulose. The transferred membranes 
were probed with specific primary anti-TLR9 mouse monoclonal 
antibody and then with the corresponding HRP-conjugated anti-
mouse secondary antibody (Amersham). As internal control a 
polyclonal antibody anti β-actin (Santa Cruz) was used. Protein 
bands were visualised by incubating the membranes with enhanced 
chemiluminescence reagent (Bio-Rad) and exposing the membranes 










6. FACS analysis 
 
PP78 cells were cultured for 24 hours and then treated with ODN 
2006 (5µM). The treated and untreated cells were harvested after 36, 
60 and 72 hours of culture. The cells were fixed in 70% ice-cold 
ethanol and than they were washed twice in PBS and stained with a 
50 µg/ml propidium (Invitrogen) and 100 µg/ml RNase solution for 30 
minutes  at 4°C.  
The cells were analyzed using a FACS flow cytometer. 
 
 
7. Proliferation assay 
 
For proliferation assay, 2x104 cells for PP78  and PP 109 were plated 
on 8-wells chamberslides and supplemented with 350 µl of complete 
culture medium. TLR9 ligands and control ODN were added at 3 
different concentrations (1µM, 3µM, 5µM) on day 1 of culture. The 
treated and untreated cells were harvested after 6, 24 hours and 72 
hours of culture, and counted into Neubauer chamber under light 
microscopy. Cell viability was then checked by trypan blue exclusion. 





8. Assay for cytokine production 
 
PP78 cells were seeded into six-well plates and supplemented with 
1.5 ml of complete culture medium. The next day, they were 
stimulated with TLR9 ligands or control ODN, with or without 
chloroquine (InvivoGen) pre-treatment; 24 hours post-stimulation, 
supernatant was collected, filtered through a 0.22-µm membrane 
filter, and interleukin (IL)-6, IL-8 and IL-10 concentrations were 




9. Nitric oxide (NO) assay 
 
The production of NO from was determined measuring the quantity of 
nitrite in the supernatant of PP78 cells exposed to ODN 2006 for 48 
hours by using the colorimetric Griess Reagent System (Promega). 
A standard reference curve with nitrite ranging from 1.56 to 100 µM 
was prepared for each essay for accurate quantification of nitrite 
levels in experimental samples. 
 









1. TLR9 expression in PCCs  
 
1.1 TLR9 mRNA expression  
 
To investigate the TLR9 expression in PCCs, RT-PCR analysis was 
performed on samples of PP78, PP109, PP117, and PP161 cells 
lines. All these samples were first run for GAPDH expression to 
ensure quality of cDNA.  
As shown in figure III.1 all PCCs showed TLR9 mRNA expression. 
The PCR products were also gel purified and sequenced to confirm 
size and identity, respectively. 
In order to obtain highly sensitive quantification of TLR9 expression 
in PCCs, we also used Real Time RT-PCR; for this analysis a 
relative quantification was performed using GAPDH as endogenous 
control gene. 
As shown in figure III.2, PP78 and PP109 cells had TLR9 levels 
comparable to ones observed in A549 cells, (human lung cancer cell 
line) used as positive control (Droemann et al., 2005; Wang et al., 
2006). In contrast, we found that TLR9 mRNA expression was higher 





in PP117 and PP161 cells than in control A549 cells (p = 0.009 and p 
= 0.0002, respectively). 





















































GAPDH (mRNA) TLR9 (mRNA)
Figure III.1: TLR9 mRNA expression in PCCs determined by RT-PCR 
Figure III.2: Quantitative comparison of the TLR9 mRNA expression in PCCs by 




































1: normalized to GAPDH mRNA levels 
*: T test 





1.2 Expression of TLR9 protein 
 
 
To confirm the RT-PCR findings, we further examined the expression 
of TLR9 protein in PCCs by immunofluorescence analysis using a 
specific anti-TLR9 mouse monoclonal antibody (Santa Cruz 
Biotecnology) that targets the extramembranous portion of human 
TLR9 (residues 1-815). All cell lines showed an intense cytoplasmic 
fluorescence using the aforementioned Ab (fig.III.3/A). 
Moreover, PP78 and PP109 cell lines were evaluated for expression 
of TLR9 protein by western blot analysis. Total proteins from various 
human cell lysates were normalized using the β-actin monoclonal 
antibody. As shown In figure III.3/B PP78 cells expressed TLR9 to a 
level comparable with A549 cells. In contrast, only weak expression 
of TLR9 protein was detected in PP109 cells. 




























Figure III.3: TLR9 protein expression in PCCs. A: Immunoflorescence analysis;   
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2. Evaluation of TLR9 mRNA expression in 
ODN-treated cells 
 
2.1  Semiquantitative PCR 
 
In order to determine whether ODNs treatment was able to modulate 
the TLR9 expression, we first performed semiquantitative RT-PCR 
on serial diluted cDNA of the TLR9-specific mRNA in PP109 cells 
stimulated with ODNs for 4 hours. 
All diluted and undiluted samples, were first analysed for GAPDH 
expression to ensure quality and quantity of cDNA (data not shown). 
As shown In figure III.4, the results revealed that the CpG ODN 
treatment induced an increase in TLR9 mRNA expression; in 
particular, the mRNA expression was increased in PP109 cells 
treated with ODN 2006 for 4 hours: RT-PCR performed in ODN 
2006-treated cells was positive in 3 of 4 replicates, versus 2 of 4, and 
1 of 4 positive results in ODN AP1-treated and untreated cells, 
respectively.  
These preliminary data suggested that the CpG-ODNs, such as ODN 



























2.2 Real Time PCR 
 
To confirm the above findings, PP109 and PP78 PCCs were treated 
with ODNs and TLR9 mRNA expression was examined by Real Time 
PCR at selected times post ODN-treatment.  
In this experiment we used GAPDH to normalise gene expression 
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Figure III.4: Analysis of TLR9 mRNA expression in ODN-treated PP109 cells by 
semiquantitative RT-PCR using undiluted or 15-fold diluted cDNA samples. 





As shown in the graphic, TLR9 mRNA levels significantly increased 
in PP109 cells treated with ODN 2006 (containing 4 CpG motifs) for 4 
hours (fig. III.5/A). 
24 hours post ODN 2006-treatment, TLR9 levels decreased until 
return to normal levels 72 hours after stimulation. 
In contrast, no significant effect was observed in PP109 cells 
exposed to ODN AP1(containing one CpG motifs). 
ODN 2006-treatment of PP78 cells also increased the receptor 
expression 4 hours post ODN-treatment, even if such an increase 
appeared less marked than in PP109 cells (fig. III.5/B). 
ODN 1826-control (without CpG motifs) didn’t induce any significant 
effect on TLR9 mRNA expression.  






























* p < 0.05 (randomisation test, Pfaffl et al., 2002) 
1 normalized to GAPDH mRNA levels 
B) 
Figure III.5: A) Expression of TLR9 mRNA in PP109 cells treated 
with 3µM ODNs; B) Expression of TLR9 mRNA in PP78 cells treated 




















































































3. Characterisation of the ODN effects on cell 
survival 
 
3.1: by trypan blue exclusion assay 
 
To investigate whether ODNs could affect the PCCs survival, PP109 
and PP78 cells were treated with ODNs for 6, 24 and 72 hours and 
cell viability was measured by trypan blue method; figure III.6 shows 
the viable cell numbers of cancer cells treated with different 
concentrations of ODN 2006, AP1, 1826 and 1826-control.  
As shown in Figure III.6, ODNs doses ranging from 1 to 5 µM were 
not cytotoxic for PP109 and PP78 cells; in fact, the percentage of cell 
death in ODN-treated cells was comparable to one observed in 
control cells. 
However, a significant reduction of the proliferation rate was 
demonstrated in PP109 and PP78 PCCs treated for 72 hours with 
ODN 2006 and ODN 1826, and in PP78 cells treated for the same 
time with ODN AP1. The results are plotted in figure III.7 (A-C). On 
the contrary, as expected, ODN 1826-control did not show any 
significant effect on PCC proliferation (fig.III.7/D). 
In summary, the ODNs containing one or more CpG motifs (ODN 
1826, ODN AP1, and ODN 2006) induced a significant reduction of 
proliferation on both cell lines 72 hours post ODN-stimulation; on the 
other hand, the control ODN showed no or minimal effect on cell 





growth. Moreover, PP109 cells appeared to be less responsive to 
CpG ODNs than PP78 cells: only the highest concentration (5µM) of 
ODN 2006 was able to induce a significant reduction of PP109 cell 
proliferation; in contrast, PP78 cells showed a significant reduction of 
proliferation after treatment with ODN 2006 and ODN AP1 at all 
doses used. In addition, the percentage reduction induced by 5 µM 
ODNs was higher than the reduction induced by 1µM ODNs (p = 
0.010 for ODN 2006 and p = 0.009 for ODN AP1). Unexpectedly, the 
ODN 1826 was effective on both cell lines when the lowest 
concentration was used (Table III.1). 















































Figure III. 6: PP78 and PP109 survival in response to ODNs (1-5µM): 
percentage of viable cells 72 hours post-treatment. 














































A) ODN 2006 
PP78 
PP109 







0 6 24 72







































B) ODN AP1 
PP78 
PP109 













































Time post ODN-treatment (hrs)





 D) ODN 1826-control 
Figure III. 7: Survival of PP109 and PP78 PCCs incubated for different time in 
presence of ODN 2006 (A), ODN AP1 (B), ODN 1826 (C) and ODN 1826- 
control (D). 


















































Reduction of PCCs proliferation 
(mean ± SD%) 
 PP78 PP109 
2006 
  
    1µM 33.2 ± 6.2* # 35.0 ± 18.7 
    3µM 48.5 ± 4.5* 30.4 ± 12.3 
    5µM 54.1 ± 4.9* 35.7 ± 3.5* 
 AP1   
    1µM 37.4 ± 5.9* ## 22.4 ± 12.2 
    3µM 48.7 ± 10.8* 12.3 ± 20.8 
    5µM 61.0 ± 6.6* 15.1 ± 3.2 
1826   
    1µM 32.5 ± 2.9* 23.3 ± 14.8* 
    3µM 21.6 ± 6.2 8.3 ± 2.4 
    5µM 20.3 ± 19.2 21.4 ± 0.5 
1826-c   
    1µM 23.0 ± 6.9 17.9 ± 5.8 
    3µM 23.8 ± 2.6 8.5 ± 1.9 
    5µM 18.3 ± 2.3 0.5 ± 4.7 
Table III.1:  Reduction of PP78 and PP109 PCC-proliferation 72 hours 
post-treatment with 1-5 µM ODNs. 
* : p < 0.05  
#  : p = 0.010 versus ODN 2006 5µM   
##  : p = 0.009 versus ODN AP1 5µM   
*, #, ##,: T test 





3.2: by FACS analysis 
 
To verify if CpG-ODNs may affect cell cycle of PCCs, PP78 cells 
were treated with ODN 2006 (5 µM), harvested at different times and 
analysed by FACS analysis. The cell cycle of PP78 cells showed an 
evident increase of the cell number in S-phase associated with a 
simultaneous decrease of cells in phase G0/G1 36 hours post ODN-
treatment; this delay in S-phase was followed by a G0/G1 arrest 
observed after 60 hours of treatment. PP78 cells, exposed to ODN 
2006 for 72 hours, showed an accumulation in the G0/G1 phase 
comparable to that observed in control cells at confluence (Fig. III.8). 
The FACS analysis with propidium iodide did not show any increase 
of the percentage of apoptotic cells between the ODN-treated and 
untreated cells.  
Our data indicate that PP78 cells are highly responsive to ODN 2006. 
In fact, this ODN, particularly rich in CpG motifs, induces an evident 
anti-proliferative effect in cancer cells and significantly modulates cell 
cycle progression.  
  




































































4. Characterisation of the viral DNA-effects on 
cell survival 
 
Our results demonstrated a significant reduction of cancer cell 
proliferation after stimulation with CpG-ODNs. To further investigate 
such a finding we carried out an experiment using, as TLR9 ligand, 
viral DNA obtained from a recently discovered human virus, TTV, 
that is highly prevalent in the human population and widely 
distributed in the host tissues (Bendinelli et al.,, 2002). The use of 
this viral DNA, containing several unmethylated CpG motifs, 
represents an useful tool to study the combined effect of these motifs 
on the TLR9. Thus, PP78 cells were treated for 72 hours with TTV 
DNA mixed with the cationic liposomes (Lipofectin® Reagent), and 
cell viability was measured by trypan blue method. Negative and 
positive controls were PP78 cells exposed to diluent or lipofectin 
reagent only, and ODN 2006, respectively.  
In order to investigate if viral DNA might interfere with the activity of 
synthetic CpG-ODNs, we have also evaluated the TTV DNA effect in 
combination with ODN 2006.  
The results revealed that the TTV-DNA mixed with lipofectin was 
able to induce, as well as ODN 2006 alone or combined with 
lipofectin, a significant reduction of the proliferation rate in PP78 cells 





(p = 0.0087) when compared to cells exposed to lipofectin only (fig. 
III.9); moreover, the combination of TTV-DNA with ODN 2006 didn’t 
modify the anti-proliferative effect induced by both ligands when used 
alone. 
In contrast to CpG-ODN-stimulated cells, TTV-DNA-treated cells 
showed a significant percentage of cell death (p = 0.0167); this effect 
was completely reversed by addition of ODN 2006.  
The experiment indicates that TTV-DNA, a natural ligand for TLR9, 
and synthetic CpG 2006 can trigger different effects on PP78 cells. 
On the other hand, the combination of both ligands resulted in a 
complete inhibition of viral-DNA-induced response. 











p = 0.0087# 
p = 0.0091# 













1 mean of three wells ± SD 
*: concentation =  5 µM 
**: 6 µg 





















 Apirogenic  H2O      +            -           +             +            +             +              
  Lipofectin         -            +            -             +           +             +         
  ODN 2006*        -            -            +             +           -              +         
  TTV DNA**        -            -             -             -            +             +         
#: T test 





5. Secretion of cytokines in response to CpG-
ODN stimulation 
 
To elucidate whether the anti-proliferative effect demonstrated in 
CpG-ODN treated cells was related to TLR9-mediated cytokine 
modulation, we further assessed the secretion from CpG-ODN 
treated PP78 cells of pro-inflammatory and anti-inflammatory 
cytokines which are particularly involved, via autocrine or paracrine 
mechanisms, in the carcinogenesis and progression of some types of 
tumor (Bellone et al., 2006). In particular, we measured the 
production of IL-6, IL-8 and IL-10 in the supernatant of untreated 
cells and of cells exposed to ODNs (2006 and 1826-control) for 24 
hours. We also evaluated the cytokine production in cells pre-treated 
with chloroquine: this drug, an inhibitor of endosomal acidification, 
has been shown to block CpG-TLR9 binding and to inhibit CpG 
containing DNA effects on immune cells (Rutz et al., 2004). To 
determine whether signalling events in pancreatic cancer cells are 
similar to those observed in immune cells, PP78 cells were treated 
with chloroquine, followed by exposure to ODN 2006. 
The results showed that IL-6 and IL-10 were not influenced by ODN- 
exposition regardless of chloroquine pre-treatment (fig.III.10/ A, B); in 
contrast, exposure to ODN 2006, but not to ODN 1826 control, 
suppressed basal IL-8 levels measured in cell culture supernatant (p 





= 0.0001; fig.III.10/C). IL-8 is up-regulated in many cancers and it’s 
associated with tumorigenesis by promoting angiogenesis and 
metastasis. Thus, our results suggest that the anti-proliferative effect 
demonstrated in CpG-ODN treated cells may really depend on the 
specific ODN 2006-induced inhibition of IL-8 production. 
Moreover, chloroquine treatment didn’t significantly abrogate the 
inhibitory CpG-ODN effect on IL-8 secretion, suggesting that the 
TLR9 signaling in pancreatic cancer cells is different than the TLR9 























































































































Figure III.10: Supernatant cytokine levels (A: IL6; B: IL-10; C: IL-8) of ODN-
treated PP78 cells. 





*: Concentration = 2 µM 
UC : Untreated Cells 
CQ : Chloroquine (10 µM)





6. NO production in CpG-ODN treated PP78 
cells 
 
Finally, ODN 2006 was evaluated for its ability to up-regulate NO 
production in PP78 cells.  
NO is an important physiological messenger and effector which 
mediates a variety of different effects in pancreatic tumor, including 
immunoregulation and cell cycle modulation (Gansauge et al., 1998). 
We evaluated the amount of NO by measuring the nitrite content in 
the supernatants of PP78 cells exposed to ODN 2006 for 48 hours. 
As shown in figure III.11, ODN 2006 treatment increased NO 
production approximately 8.5-fold, compared to untreated control. 
This result suggests that the ODN 2006-induced NO production may 
play a role in the anti-proliferative effect observed in CpG ODN 
treated PP78 cells.  
















































p = 0.0028* 
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Figure III.11: NO production from ODN-treated PP78 cells. 
ODN 2006 
*: T test 









Although progresses have been made in the medical management of 
pancreatic cancer over the last decade, many other thinks have to be 
still made on this matter. The existing therapeutic approaches are 
poorly effective (Freelove and Walling, 2006), and there is an urgent 
need to search for novel, effective drugs for the treatment of this type 
of cancer. 
CpG DNAs represent a promising therapeutic strategy in various 
diseases and the recent demonstration of their antitumor activity due 
to activation of immune cells and induction of cytokines is promoting 
the evaluation of these novel drugs in clinical trials of cancer patients. 
Synthetic CpG-ODNs designed to specifically activate TLR9, might 
have several potential applications in cancer; for example, they may 
enhance the development of an immune response by increasing 
antigen presentation after antigen release by the tumor or by 
suppressing regulatory T cells. Moreover, CpG-ODNs could 
potentially induce apoptosis and/or affect the proliferation of TLR9-
expressing tumor cells and increase the immunogenicity of cells that 
express the receptor. All these mechanisms could lead to enhanced 
therapeutic effects of CpG-ODNs when combined with conventional 





therapies (Wooldridge and Link, 2003; Wang, et al., 2005a; 
Pashenkov et al., 2006; Damiano et al., 2007; Krieg, 2008; Vicari et 
al., 2009). 
Increasing evidence in experimental animals shows that CpG-ODNs 
exert antitumor activity against different tumor types, including both 
solid tumors and hematologic malignancies. With respect to 
pancreatic cancer, administration of synthetic CpG-ODNs has 
recently demonstrated the ability to induce significant growth 
inhibitory effects on orthotopically xenotransplanted pancreatic 
tumors in highly immunodeficient mice; furthermore, the combined 
use of CpG-ODNs with chemotherapy improved survival in orthotopic 
murine models of human pancreatic ductal adenocarcinoma (Pratesi 
et al., 2005; Tepel et al., 2006). 
Although all of these studies showed promising results, none have 
attempted to explain the mechanism of action of TLR9 ligands in the 
context of pancreatic tumor.  
In order to fully analyze and further investigate the biological CpG-
ODN effects in pancreatic cancer, we utilized in the present study 
four human PCCs previously established from tumor specimens 
surgically removed from patients with PDA. 
Our first objective was to examine the expression of TLR9 in PCCs at 
both transcriptional and protein levels. 





Assessing TLR9 expression within pancreatic tumor cells may be 
important to increase the rationale for treatment with CpG-ODNs in 
PDA and might allow identification in the clinical trials of a subset of 
patients who could benefit at the best of this therapeutic approach. 
We demonstrated that bothTLR9 mRNA and protein were expressed 
in all four cells lines examined, although different cell lines had 
different basal levels of TLR9 expression. 
In humans, TLR9 has been described to be mainly expressed in B-
lymphocytes, monocytes and plasmacytoid dendritic cells (Takeshita 
et al., 2001). However, there is now increasing evidence of TLR9 
expression in non-immune cells including cancer cells (Droemann et 
al., 2005; Pedersen et al., 2005; Lee et al., 2007; Meng et al., 2008). 
In this work, for the first time, we have shown TLR9 expression in 
PCCs; this suggests that also pancreatic tumors may be responsive 
to TLR9 agonists. 
In order to determine whether CpG-ODN treatment alters TLR9 
expression, we arbitrarily chose two of the PCCs, PP78 and PP109 
cell lines, which have low and high differentiation levels, respectively 
(Chifenti et al., 2008).  
PP78 and PP109 PCCs were treated with CpG or control ODNs and 
the TLR9 expression was then examined: administration of CpG-
ODNs to both PCCs caused a significant increase of TLR9 mRNA 
expression, while the control ODNs had a modest effect on PCCs. 





These data indicate that the CpG-ODNs may be able to act directly 
on PCCs by modulating their own receptor transcription. 
Upon finding expression of TLR9 in PCCs, we further investigated 
whether CpG-ODNs could directly affect the in vitro characteristics of 
cancer cells; the CpG-ODNs effects in PP78 and PP109 PCCs were 
first determined using trypan blue method for cell survival 
assessment. Our data showed that CpG or control ODNs, within the 
concentration range tested, did not induce cell death in PCCs. 
However, we observed a significant reduction of proliferation rate in 
both PP78 and PP109 cell lines incubated for three days with TLR9 
agonists. This anti-proliferative effect was correlated with the number 
of CpG dinucleotide motifs contained in ODN sequences suggesting 
a possible direct involvement of TLR9 in the recognition of CpG 
motifs in PCCs (krieg, 2003). Moreover, we observed that PP78 cells 
were more responsive to CpG motifs than PP109 cells. Although not 
completely understood, this finding indicates a certain degree of 
heterogeneity in the response of different PCCs to specific CpG-
ODNs. 
Our results support the observations reported in an early study which 
examined the effects of CpG-ODNs in murine prostate cancer cells, 
revealing that TLR9 ligands decreased tumor cell proliferation. 
Similar effects were seen using human prostate and colon cancer 





cell lines (Shen et al., 2002; Rayburn et al., 2006; Rayburn et al., 
2007). 
In order to investigate the molecular basis for the anti-proliferative 
effect observed in CpG-ODNs treated PCCs, cell cycle distribution 
was monitored by flow cytometry in PP78 cells incubated with CpG-
ODN 2006 for selected times. Our data revealed a delay in S-phase 
followed by a G0/G1 arrest in CpG-ODN treated PP78 cells; this 
result suggests that CpG-ODN-induced cell cycle modulation may 
really represent the basis for the anti-proliferative effect observed in 
CpG-ODN treated PCCs. 
In addition to the synthetic CpG-ODN ligands, we showed that also 
viral DNA was able to induce a significant reduction of the 
proliferation rate in PP78 cells. 
In particular, we used viral DNA derived from TTV, human DNA virus 
highly prevalent in the general population and widely distributed in 
the host tissues (Bendinelli et al, 2002). 
Unlike CpG-ODNs, TTV-DNA induced in PP78 cells a significant 
percentage of cell death, but this effect was completely reversed by 
addition of CpG-ODNs. This finding could be explained by the 
chemical modifications of the structural characteristics of synthetic 
CpG ODNs which show higher stability than natural TLR9 ligands 
such as viral DNAs. However, further studies are necessary to clarify 





how viral DNA interacts with TLR9 in PCCs and how it would affect 
treatment with CpG-ODNs. 
Recent studies have demonstrated that accelerated pancreatic 
cancer growth is not only due to mutations of genes involved in 
regulating the cell cycle, but also to an imbalance between 
stimulatory and inhibitory factors, mainly cytokines. (Giavazzi et al., 
1990; Basso and Plebani, 2000; Detjen et al., 2001; Bellone et al., 
2006). 
For this reason we have ruled out the possibility that CpG-ODN effect 
on tumor proliferation may be related to a direct TLR9-mediated 
cytokine modulation in PCCs. 
The measurement of cytokine secretion from stimulated PP78 cells 
revealed a significantly decreased release of IL-8 in response to 
CpG-ODN treatment. 
Many studies have demonstrated that IL-8 renders human pancreatic 
cancer cells more tumorigenic and metastatic; this cytokine is 
involved, via autocrine and paracrine mechanisms, in the 
carcinogenesis and progression of some type of tumor by attracting 
inflammatory cells, promoting new vessel formation in growing 
tumors, and altering cell adhesion molecules and chemotaxis (Shi et 
al., 1999; Li et al., 2003). 
Thus, the specific CpG-ODN induced inhibition of IL-8 may provide 
an explanation for growth inhibition of PCCs by TLR9 ligands. 





Our finding has several important implications for future studies: it will 
be particularly interesting to see whether IL-8 is the only cytokine 
suppressed by CpG-ODNs; in fact, it is likely that a whole cocktail of 
proinflammatory cytokines becomes affected by ODN-treatment, 
leading to the observed anti-proliferative response. 
In the present study we also examined the effect of TLR9 ligands on 
the production of NO in the cultured PCCs. NO is an important 
signaling molecule that acts in many tissues to regulate a diverse 
range of physiological and cellular processes (Xie, et al., 1995; 
Forrester et al., 1996; Gansauge et al., 1998). 
Our results showed that CpG-ODN treatment was able to up-regulate 
NO production in PP78 cells. This up-regulation of NO by TLR9 
agonists may have significant roles in the regulation of cell cycle 
and/or of cytokine production in PCCs. 
In conclusion, for the first time we demonstrated the expression of 
TLR9 in PCCs. Our results also showed that synthetic CpG ODNs, 
as well as viral DNA, probably through TLR9-activation, may exert an 
anti-proliferative effect in pancreatic carcinoma cells; such an effect 
might depend on the CpG-DNA induced modulation of endogenous 
mediators such as IL-8 and NO that play an important role in the 
regulation of tumor growth and metastasis. 





Although the possible therapeutic value of these findings remains to 
be determined, our data, taken together, provide further evidence for 
pursuing TLR9 ligands as a potential therapeutic agent in PDA.
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